New data presented at CHEST 2026 highlights how Biodesix’s Nodify Lung assay integrates with PET imaging and improves follow-up adherence.
Biodesix announced multiple presentations at the CHEST 2026 annual meeting evaluating the integration of its Nodify Lung testing into routine clinical care for pulmonary nodules. The research includes sponsored and independent clinical evaluations examining diagnostic test sequencing, clinical utility, and patient follow-up adherence in clinical practice.
The presentations feature new analyses from the CLARIFY study, which has enrolled more than 2,000 patients receiving Nodify Lung testing during routine care. The findings explore comparisons and diagnostic sequencing alongside positron emission tomography (PET) imaging to help clinicians determine the optimal placement of blood-based testing in diagnostic workflows.
“The growing focus on real-world implementation reflects an important evolution in the evidence supporting Nodify Lung testing,” says Scott Hutton, CEO of Biodesix, in a release. “The discussion is increasingly moving beyond whether blood-based biomarkers can accurately assess lung nodule risk to how they can be routinely incorporated into structured care pathways and used alongside imaging.”
Assessing Diagnostic Sequencing and Imaging Integration
Biodesix-sponsored presentations at the meeting focus on optimizing diagnostic pathways and assessing blood-based biomarker utility across specific nodule presentations.
Michael Kammer, PhD, head of radiomics at Biodesix, will present findings from three company-sponsored studies:
- An inverse probability of treatment weighting analysis evaluating PET imaging paired with blood-based biomarkers compared to biomarkers alone for pulmonary nodule management.
- A counterfactual analysis of real-world data from the CLARIFY study to optimize non-invasive diagnostic test sequencing in pulmonary nodule workflows.
- An evaluation of the diagnostic performance of tumor-associated autoantibodies in patients presenting with ground glass opacity pulmonary nodules.
In addition, Sonali Sethi, MD, of the Cleveland Clinic, is scheduled to lead a clinical education session examining how to implement biomarkers into structured nodule management care pathways.
Independent Studies on Adherence and Risk Re-Stratification
The conference program also includes investigator-led research evaluating how proteomic testing functions in diverse practice settings.
Arlnaldo Cruz, MD, of Wyckoff Heights Medical Center, will present data on utilizing proteomics risk stratification to reduce loss to follow-up among pulmonary nodule patients managed in a safety-net clinic. In another presentation, Jay Xiong, DO, of Rosalind Franklin University of Medicine and Science and Aurora Medical Center Kenosha, will review bidirectional risk re-stratification using proteomic biomarker testing in two patients with identical pre-test malignancy risks.
Beyond nodule risk stratification, Syed Naqvi, MD, also of Rosalind Franklin University and Aurora Medical Center Kenosha, will present a case report evaluating rapid, concordant EGFR detection using Biodesix’s IQ Lung liquid biopsy compared to standard tissue testing in stage IVB non-small cell lung cancer.
ID 182169642 © Irina Naykina | Dreamstime.com
